3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
59
Dermatologic
23
Thoracic
21
Tumor-Agnostic
15
Gastrointestinal
14
Gynecologic
6
Sarcoma
3
Genitourinary
3
CNS
2
Breast
2
Other neoplasm
1
Other
1
Lymphoid
1
Endocrine
1
Classical hematology
1
Conditions
Lymphoma
666
Lymphoma, Non-Hodgkin
593
Leukemia, Lymphocytic, Chronic, B-Cell
535
Precursor Cell Lymphoblastic Leukemia-Lymphoma
485
Lymphoma, Follicular
418
Lymphoma, Large B-Cell, Diffuse
379
Leukemia
358
Hodgkin Disease
354
Lymphoma, Mantle-Cell
306
Leukemia, Myeloid, Acute
250
Multiple Myeloma
237
Myelodysplastic Syndromes
214
Lymphoma, B-Cell, Marginal Zone
196
Recurrence
195
Burkitt Lymphoma
189
Waldenstrom Macroglobulinemia
155
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
130
Lymphoma, B-Cell
127
Neoplasms
118
Lymphoma, T-Cell, Cutaneous
116
Lymphoma, Large-Cell, Anaplastic
113
Hematologic Neoplasms
103
Lymphoma, Large-Cell, Immunoblastic
100
Mycosis Fungoides
95
Myeloproliferative Disorders
94
Sezary Syndrome
86
Lymphoma, T-Cell, Peripheral
83
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
81
Lymphoma, T-Cell
74
Primary Myelofibrosis
70
Interventions
spartalizumab
1
pembrolizumab
1
Ipilimumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Carcinoma, Squamous Cell
×
Lymphoid
×
Clear all
NCT03058289
2025-02-27
IT-01
Intensity Therapeutics, Inc.
Phase 1/2
Completed
111 enrolled
21 charts